UK Presents New Licensing Pathway For Innovative Drugs

MHRA To Be ‘Enabling Regulator’

A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.

Hands_Sun_Puzzle_Pieces
The MHRA is putting together an integrated regulatory system • Source: Shutterstock

On 1 January 2021 the UK regulator, the MHRA, will launch a new licensing pathway for innovative drugs that will include an “innovative medicine designation” and a new “target development profile” for each product to act as a roadmap for its development.

The new pathway, which envisages “supervised early use” of new products through “adaptive authorization,” is part of a new, integrated...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

More from Europe